Meeting
2015 Gastrointestinal Cancers Symposium
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071).
Authors
Markus Hermann Moehler
Johannes-Gutenberg University Mainz, Mainz, Germany
Markus Hermann Moehler , Arno Schad , Murielle E. Mauer , Carlo G. M. Messina , Jestinah. M. Mahachie John , Istvan Lang , Eric Van Cutsem , João Freire , Manfred P. Lutz , Arnaud Roth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01123473
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 80)
DOI
10.1200/jco.2015.33.3_suppl.80
Abstract #
80
Poster Bd #
B30
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
First Author: Manish A. Shah
Poster
2021 Gastrointestinal Cancers Symposium
A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).
First Author: Yelena Y. Janjigian
Poster
2020 ASCO Virtual Scientific Program
Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).
First Author: Sun Young Rha
Poster
2018 ASCO Annual Meeting
Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.
First Author: Feng Wang